Primary drying raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
Lyophilization removes water by freezing a material and then lowering pressure so ice changes directly to vapor. The process relies on sublimation, the phase transition from solid to gas without an intermediate liquid state. Because the material remains frozen during primary drying, the structure often stays porous. This porous matrix can rehydrate quickly when water is added back. The low pressure also allows vapor to leave the solid matrix without boiling.
A typical cycle begins with freezing, which fixes the material into a solid and determines ice crystal size. Primary drying then raises heat under vacuum so ice sublimes, often near or below the collapse temperature of the formulation. Secondary drying removes bound water that remains after ice is gone, usually by gently warming the product. Each stage balances heat input against pressure to avoid melting or structural damage. Temperature probes and pressure sensors guide the transition between stages.
In practice, lyophilization is slower and more energy intensive than simple drying. Cycle times can range from hours to several days depending on load, container, and formulation. Amorphous materials may require excipients that help preserve structure during freezing and drying. The method is widely used for biological materials, pharmaceuticals, and foods where heat drying would cause unacceptable change. Open questions remain about scaling cycles between laboratory and production equipment, and this gap affects technology transfer.
Quality control for lyophilized materials includes visual inspection of the cake, measurement of residual moisture, and tests for reconstitution time. An acceptable cake is typically uniform and may be slightly porous; shrinkage, meltback, or cracks can indicate process deviations. Analytical methods such as Karl Fischer titration, thermogravimetric analysis, and near-infrared spectroscopy quantify water content. Reconstitution time is recorded because a very slow or incomplete dissolution can signal collapse or aggregation. Stability studies compare samples stored under defined temperature and humidity conditions over months or years.
Regulatory expectations for lyophilized products focus on consistent manufacture and documented stability. Batches are often monitored for moisture, appearance, potency, and sterility where applicable. Process parameters such as shelf temperature, chamber pressure, and drying time are recorded and controlled within validated ranges. Open questions remain about how best to predict long-term stability from short accelerated studies, especially for complex biologics. Variations in freezing rate and ice crystal size can produce differences that are not always visible but may affect performance.
| Property | Value | Notes |
|---|---|---|
| Common synonym | Freeze-drying | Same dehydration operation |
| Typical vacuum | 10-100 Pa | Pressure during primary drying |
| Primary drying temperature | -40 to -10 °C | Below collapse temperature for many formulations |
| Cycle duration | 12-72 hours | Varies with load, container, and formulation |
| Key phase change | Sublimation | Solid ice to water vapor |
== Mechanism of action == Telithromycin prevents bacteria from growing, by interfering with their protein synthesis. Telithromycin binds to the subunit 50S of the bacterial ribosome, and blocks the progression of the growing polypeptide chain. Telithromycin has over 10 times higher affinity to the subunit 50S than erythromycin. In addition, telithromycin strongly bind simultaneously to two domains of 23S RNA of the 50 S ribosomal subunit, where older macrolides bind strongly only to one domain and weakly to the second domain. Like many other protein synthesis inhibitors, telithromycin can also inhibit the formation of ribosomal subunits 50S and 30S.
=== Endothelial colony forming cell === Endothelial colony forming cells are a late outgrowth cell type; that is, they are only isolated after significantly longer culture than CFU-Hill cells. ECFCs are isolated by plating peripheral blood mononuclear fraction on collagen-coated plates, removing non-adherent cells, and culturing for weeks until the emergence of colonies with a distinctive cobblestone morphology. These cells are phenotypically similar to endothelial cells and have been shown to create vessel-like structures in vitro and in vivo. In 2019, David Smadja described a standardized protocol for the isolation and culture of endothelial colony-forming cells (ECFCs) in humans. This was followed in 2023 by a publication surveying laboratory practices among teams working with these cells, conducted under the auspices of the International Society on Thrombosis and Haemostasis Vascular Biology Scientific Subcommittee. In 2025, a review emphasized the unique vasculogenic and immunomodulatory properties of cord blood-derived ECFCs (CB-ECFCs), highlighting their high proliferative capacity, immune-privileged status, and therapeutic potential in vascular regeneration and tissue engineering.
=== Purine metabolism === GMP synthase is the second step in the generation of GMP from IMP; the first step occurs when IMP dehydrogenase generates XMP, and then GMP synthetase is able to react with glutamine and ATP to generate GMP. IMP may also be generated into AMP by adenylosuccinate synthetase and then adenylosuccinate lyase.
The Administrative and Program Enrichment Core coordinates Center activities, provides biostatistical support, promotes community engagement, and facilitates career development through seminars, workshops, and the internationally recognized Masoro-Barshop Conference on Aging. The Aging Animal and Functional Assessment Core offers access to aged animal colonies, longevity studies, and comprehensive assessments of physical and physiological function. The GeroMetabolism Core provides advanced metabolomic, lipidomic, and metabolic phenotyping capabilities that enable investigators to examine metabolic mechanisms underlying aging and age-related diseases. The Pathology Core delivers expert histopathologic evaluation and disease phenotyping across multiple organ systems, while the Pharmacology and Drug Design Core supports the identification, optimization, and evaluation of pharmacological interventions targeting aging pathways. Finally, the Research Development Core expands aging research by providing pilot funding, mentorship, trainee support, and access to Center resources for investigators both within UT Health San Antonio and across the United States. A distinguishing strength of the San Antonio Nathan Shock Center is its commitment to developing the next generation of geroscientists. Through pilot grant programs, mentorship initiatives, trainee internships, educational workshops, and collaborative research opportunities, the Center provides critical support for early-stage investigators pursuing careers in aging research.
Sources: en.wikipedia.org
=== Pharmacodynamics === 4-HO-NiPT shows affinity for serotonin receptors, including for the serotonin 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7 receptors (Ki = 229–2,461 nM). Conversely, it did not show affinity for the serotonin 5-HT1B or 5-HT5A receptors, whereas the serotonin 5-HT1A receptor was not reported. 4-HO-NiPT is a partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, with EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values of 24 nM (88.4%), 188 nM (69.9%), and 963 nM (45.2%), respectively. It was also a weak agonist of other serotonin receptors, including the serotonin 5-HT1B, 5-HT1E, 5-HT1F, and 5-HT7A receptors (EC50 = 1,400–23,000 nM, Emax = 20.4–123%), but not of the 5-HT1A, 5-HT1D, 5-HT4, 5-HT5A, or 5-HT6 receptors. In contrast to norpsilocin, but similarly to psilocin and certain other N-monoalkyltryptamines like 4-HO-NET, 4-HO-NPT, 4-HO-NALT, and 4-HO-NBnT, the drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It showed 30-fold lower potency than psilocin in this action in mice, but produced about the same maximal response. Similarly to 4-HO-NiPT, other N-monoalkyltryptamines were also much less potent than psilocin, in the range of 10- to 26-fold less potent. In addition to the head-twitch response, 4-HO-NiPT produces hypothermia in rodents. 4-HO-NiPT is a known metabolite of 4-AcO-DiPT and presumably also of 4-HO-DiPT.
Certain lithium compounds, also known as lithium salts, are used as psychiatric medication, primarily for bipolar disorder and for major depressive disorder. Lithium is taken orally (by mouth). Common side effects include increased urination, shakiness of the hands, and increased thirst. Serious side effects include hypothyroidism, diabetes insipidus, and lithium toxicity. Blood level monitoring is recommended to decrease the risk of potential toxicity. If levels become too high, diarrhea, vomiting, poor coordination, sleepiness, and ringing in the ears may occur. Lithium is teratogenic and can cause birth defects at high doses, especially during the first trimester of pregnancy. The use of lithium while breastfeeding is controversial; many international health authorities advise against it, and the long-term outcomes of perinatal lithium exposure have not been studied. The American Academy of Pediatrics lists lithium as contraindicated for pregnancy and lactation. The United States Food and Drug Administration (FDA) categorizes lithium as having positive evidence of risk for pregnancy and possible hazardous risk for lactation. Lithium salts are classified as mood stabilizers. Lithium's mechanism of action is not known. In the nineteenth century, lithium was used in people who had gout, epilepsy, and cancer. Its use in the treatment of mental disorders began with Carl Lange in Denmark and William Alexander Hammond in New York City, who used lithium to treat mania from the 1870s onwards, based on now-discredited theories involving its effect on uric acid.
== Research and Clinical Frameworks == GCLS faculty and researchers have contributed to publications addressing the development of longevity medicine as a structured field of clinical practice and medical education. A 2025 Biogerontology perspective, authored by Dominik Thor, David Barzilai, Yu-Xuan Lyu and Luiza Spiru, proposed a framework for incorporating longevity-related competencies into continuing medical education and medical curricula. The authors listed GCLS affiliations. Researchers affiliated with GCLS also contributed to the peer-reviewed review article "Toward responsible longevity medicine: Swiss framework for healthy longevity medicine clinics." Published in Longevity, the paper proposed a voluntary framework addressing clinical governance, evidence appraisal, patient safety, data governance and the responsible translation of longevity interventions into clinical practice.
inosine (I, Ino) A naturally occurring, non-canonical nucleoside consisting of a hypoxanthine base with its N9 nitrogen bonded to the C1 carbon of a ribose sugar. Inosine may be incorporated into certain RNA molecules such as the anticodons of some transfer RNAs, and occurs as an intermediate in the breakdown of adenosine to uric acid and in the recycling of adenosine by salvage pathways.
It was this achievement that earned him his first Nobel prize in Chemistry in 1958. This discovery was crucial to the later sequence hypothesis of Francis Crick for developing ideas of how DNA codes for proteins.
Sources: en.wikipedia.org
Primary drying removes ice by sublimation under vacuum. Secondary drying removes water that is bound to the material, often by warming the product after most ice has left. Both stages occur below temperatures that would cause unwanted melting.
Sublimation requires the solvent to remain solid so vapor leaves without passing through a liquid phase. If the product melts, the porous structure can collapse and drying becomes uneven. Maintaining frozen conditions preserves the intended physical form.
No, freeze-drying is a dehydration method, not a sterilization step. It can reduce water activity and limit microbial growth during storage, but it does not reliably kill microbes or remove endotoxins. Sterility must come from separate validated processes.
Most are held in sealed containers at controlled temperatures, often 2–8 °C, while some require frozen storage. Protection from moisture and light helps preserve the dry matrix. Exact conditions are set by the manufacturer or study protocol.